Press Release

Melinta Therapeutics to Present at Upcoming Investor Conferences

September 25, 2018

NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, President and CEO of Melinta, will present at the following upcoming investor conferences:

  • 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Monday Oct. 1 at 8:55 a.m. Eastern Time. A webcast can be accessed from the following URL: http://wsw.com/webcast/cantor7/mlnt/.
     
  • Ladenburg Thalmann 2018 Healthcare Conference in New York, NY on Tuesday Oct. 2 at 10:00 a.m. Eastern Time. A webcast can be accessed from the following URL: http://wsw.com/webcast/ladenburg4/mlnt/.

Live and archived webcasts of the presentations will also be accessible from Melinta’s Investor Relations website at http://ir.melinta.com/.

About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela® (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.

For More Information:

Media Inquiries:
David Belian
(203) 848-6276

Investor Inquiries:
Lisa DeFrancesco
(908) 617-1358

Melinta Therapeutics

Source: Melinta Therapeutics

Melinta Therapeutics, Inc. ©2018 ALL RIGHTS RESERVED | Terms of Use